Connection
Nanette Santoro to Patient Reported Outcome Measures
This is a "connection" page, showing publications Nanette Santoro has written about Patient Reported Outcome Measures.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.180 |
|
|
|
-
Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause. 2020 12; 27(12):1350-1356.
Score: 0.137
-
Shapiro C M M, Cano A, Nappi RE, Santoro N, English ML, Mancuso S, Morga A, Siddiqui E, Valluri U, Ottery FD. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas. 2024 Aug; 186:107999.
Score: 0.043